Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives

ACS Nano, Journal Year: 2018, Volume and Issue: 12(11), P. 10636 - 10664

Published: Oct. 17, 2018

The microenvironment characteristics of solid tumors, renowned as barriers that harshly impeded many drug-delivery approaches, were precisely studied, investigated, categorized, divided, and subdivided into a complex diverse barriers. These categories further studied with particular perspective, which makes all found in solid-tumor micromilieu turn different types stimuli, considered triggers can increase hasten drug-release targeting efficacy. This review gathers data concerning the nature micromilieu. Past research focused on treatment such recent efforts employed for engineering smart nanoarchitectures utilization specified stimuli categories, possibility combining more than one much-greater enhancement, examples approved already translated clinically well obstacles faced by use these nanostructures, and, finally, an overview possible future implementations smart-chemical design more-efficient drug delivery theranostic systems making nanosystems much-higher level specificity penetrability features.

Language: Английский

---

MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside

Targeted Oncology, Journal Year: 2020, Volume and Issue: 15(3), P. 261 - 278

Published: May 25, 2020

Non-coding RNAs represent a significant proportion of the human genome. After having been considered as 'junk' for long time, non-coding are now well established playing important roles in maintaining cellular homeostasis and functions. Some show cell- tissue-specific expression patterns specifically deregulated under pathological conditions (e.g. cancer). Therefore, have extensively studied potential biomarkers context different diseases with focus on microRNAs (miRNAs) (lncRNAs) several years. Since their discovery, miRNAs attracted more attention than lncRNAs research studies; however, both families to play an role gene control, either transcriptional or post-transcriptional regulators. Both can regulate key genes involved development cancer, thus influencing tumour growth, invasion, metastasis by increasing activation oncogenic pathways limiting suppressors. Furthermore, also emerging mediators drug-sensitivity drug-resistance mechanisms. In light these premises, number pre-clinical early clinical studies exploring new therapeutics. The aim this review is summarise latest knowledge use therapeutic tools cancer treatment.

Language: Английский

---

Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization

Nature Protocols, Journal Year: 2019, Volume and Issue: 14(4), P. 1027 - 1053

Published: March 4, 2019

Language: Английский

---

Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems

ACS Nano, Journal Year: 2018, Volume and Issue: 12(7), P. 6830 - 6842

Published: July 5, 2018

Extracellular vesicles (EVs) are recognized as nature's own carriers to transport macromolecules throughout the body. Hijacking this endogenous communication system represents an attractive strategy for advanced drug delivery. However, efficient and reproducible loading of EVs with therapeutic or imaging agents still a bottleneck their use delivery system. Here, we developed method modifying cell-derived through fusion liposomes containing both membrane soluble cargoes. The functionalized was triggered by polyethylene glycol (PEG) create smart biosynthetic hybrid vectors. This versatile proved be enrich exogenous lipophilic hydrophilic compounds, while preserving intrinsic content biological properties. Hybrid improved cellular efficiency chemotherapeutic compound factor 3-4, compared free drug-loaded liposome precursor. On one side, allows biocamouflage enriching lipid bilayer inner compartment biogenic molecules. other proposed enables EV loading, pharmaceutical development adaptable activity property.

Language: Английский

---

A review on exosomes application in clinical trials: perspective, questions, and challenges

Cell Communication and Signaling, Journal Year: 2022, Volume and Issue: 20(1)

Published: Sept. 19, 2022

Abstract Background Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological pathological processes, show substantial promise novel treatment strategies for diseases. Methods In this review study, we studied numerous articles over the past two decades published on application exosomes different diseases well perspective challenges field. Results The main clinical using them a biomarker, cell-free therapeutic agents, drug delivery carriers, basic analysis exosome kinetics, cancer vaccine. Different from human or plant sources utilized various trials. Most researchers used circulatory system biomarker experiments. Mesenchymal stem (MSCs) dendritic (DCs) widely held cell use. MSCs-derived commonly inflammation delivery, while DCs-exosomes induce response patients. However, faces questions challenges. addition, translation exosome-based trials is required conform specific good manufacturing practices (GMP). review, summarize according type disease. We also address regarding kinetics applications. Conclusions promising platforms many This exciting field developing hastily, understanding underlying mechanisms that direct observed roles remains far complete needs further multidisciplinary research working with these small vesicles.

Language: Английский

---